"While discontinuing the NEO program was a difficult decision..."
Wow. Just wow.
Dew was once pretty high on NEO.
Welp, so much for that one. Another one bites the dust.
No surprise at all.
So the hype about all those listed catalysts is just that - 'hype'. Wait till EOY to see how many more catalysts are duds as reflected by the market response (rather than someone posting on this MB, including you/me/she/it).
Cash balance anticipated to extend into 2021
How many times will they seek refuge in false/misleading statements using words like anticipated, estimated etc. ?
ADXS-PSA: Prostate Cancer – The company recently reported updated data for its Phase 1/2 KEYNOTE-046 study of ADXS-PSA, alone and in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for unselected and advanced patients with metastatic castration-resistant prostate cancer (“mCRPC”).
The median overall survival for this patient population in the combination arm was 33.6 months (95% CI, range 15.4-33.6 months). These results are encouraging as the patient population in the combination arm (n=37) had high Gleason scores (9), MSI-high negative status, visceral metastatsis in 30%, prior chemotherapy in 57% and one to two prior next generation hormonal agents in >80% of patients. The company is in discussions with potential partners regarding opportunities to expand or advance this mCRPC program.
Company has been in discussion since years for partners in many ways - HER2, NEO,etc. etc. Nothing special here. Any partner would run away by looking at the range of the CI 15.4 - 33.6 months, that cries out loud about 2 issues - low sample size, unimpressive data.
News 
Market Data 
Discover 
